Tempus AI (TEM) and NYU Langone Health announced a multi-year strategic collaboration aimed at transforming cancer care through advanced molecular profiling and data-driven insights. The collaboration will support NYU Langone Health’s Center for Molecular Oncology at the Laura and Isaac Perlmutter Cancer Center.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEM:
- Tempus AI, Northwestern Medicine collaborate on genomic testing
- Tempus AI Reports Strong Preliminary 2025 Revenue Growth
- Tempus AI (TEM) Tops $1.1B in Total Contract Value as Pharma Demand for AI Tools Surges
- Tempus AI announced TCV of more than $1.1B
- Tempus AI price target lowered to $76 from $88 at TD Cowen